Drug Trial Radar · NCT00223964
Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients
Last checked: Nov 20, 2026Latest source record: Aug 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Jun 2003
Primary completion
Oct 2003
Sponsor
- Lead sponsor
- Watson PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.
Conditions
- Anemia
Interventions
Ferrlecit (sodium ferric gluconate complex in sucrose injection)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate and compare effectiveness of two Ferrlecit® doses in increasing hemoglobin in iron-deficient pediatric hemodialysis patients requiring repletion iron therapy.Time frame: 2 weeks
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
Stanford, California
Site not named
Boston, Massachusetts
Site not named
Kansas City, Missouri
Site not named
The Bronx, New York
Site not named
Seattle, Washington
Site not named
Aruascalientes, Mexico
Site not named
Mexico City, Mexico
Site not named
Bialystok, Poland
Site not named
Gdansk, Poland
Site not named
Krakow, Poland
Site not named
Lodz, Poland
Site not named
Lublin, Poland
Site not named
Szczecin, Poland
Site not named
Torum, Poland
Site not named
Wroclaw, Poland
Site not named
Zabrze, Poland
Site not named
Bashkortostan, Russia
Site not named
Moscow, Russia
Site not named
Saint Petersburg, Russia
Site not named
Tartarstan, Russia
Site not named
Belgrade, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.